Aitia Platform
AI-powered causal inference platform for drug discovery and development
Platform · Cloud SaaSCompany source
Company profile
About Aitia
Aitia is a biotechnology company focused on transforming drug discovery and development through advanced artificial intelligence and computational biology approaches. The company develops AI-powered platforms that analyze complex biological systems to identify novel therapeutic targets and optimize drug development pathways. By integrating multi-omics data, systems biology, and machine learning, Aitia aims to accelerate the discovery of effective treatments for complex diseases. The company's technology platform enables researchers and pharmaceutical partners to better understand disease mechanisms, predict drug responses, and reduce the time and cost associated with bringing new therapies to market. Aitia serves pharmaceutical companies, biotechnology firms, and research institutions seeking to enhance their drug discovery capabilities through computational approaches.
Company description Aitia official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Aitia?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Biotechnology firms
- Pharma
- Research institutions
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease.Biochemical pharmacology · Dec 1, 2025
Development and validation of a HPLC-DAD method for determining the content of tryptamines in methanolic extracts of fruiting bodies of mushrooms belonging to species of the Psilocybe genus.Talanta · Aug 1, 2025
Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer.iScience · Jun 21, 2024
Reliable Identification Schemes for Asset and Production Tracking in Industry 4.0.Sensors (Basel, Switzerland) · Jul 2, 2020
Minilaparotomy for early gastric cancer.Hepato-gastroenterology · Jan 1, 2003
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Aitia
Recent articles published on Aitia's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.